Adicet Bio Inc., a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies ...

Will support clinical development of Nirsum’s lead development candidate, NRS-033.

Dr. Marc Damelin possesses extensive industry experience in oncology drug discovery and development across a variety of ...

Evidence of efficacy and safety data support the potential for vatiquinone to fill the significant unmet need for patients ...

A Phase 2 study showed encouraging results with Trodelvy as a second-line treatment for extensive-stage small cell lung ...

Prasinezumab continues to be well tolerated and no new safety signals were observed.

Great Bay Bio (GBB) announced today the first close of its Series B financing round, led by a strategic investment ...

Biomedicines as part of its efforts to drive growth and innovation in the biopharmaceutical sector. Established in 2021 and ...

Demonstrates its commitment to providing quality, cost-saving treatment options to clinicians and the patients they serve.

In anticipation of restarting clinical studies of various DPX formulations and initiating new preclinical studies, BioVaxys ...

With a total area exceeding 16,000 square meters, the new facility houses the company's production, quality, data, and ...

Partnership leverages PHICS technology to bring together a kinase and target of interest to modulate protein function.